Citryll has successfully dosed the first patient in its Phase IIa clinical study called “Citydream,” which is evaluating CIT-013, a first-in-class monoclonal antibody, in people with moderately active rheumatoid arthritis, according to the company. The randomized, double-blind, placebo-controlled, multi-center trial across Europe will assess CIT-013’s efficacy, safety, and tolerability. It plans to enroll 88 participants for a six-week treatment period, followed by an open-label extension to further evaluate outcomes.
To support the clinical strategy, Citryll has formed an RA Clinical Advisory Board composed of leading experts to guide development across rheumatoid arthritis and other autoimmune indications. Citydream builds on the successful completion of Citryll’s first-in-human Phase I study, which included repeat dosing in rheumatoid arthritis patients, and follows an €85 million Series B funding round.
Citryll said that CIT-013 operates via a unique dual mechanism—enhancing clearance of existing neutrophil extracellular traps (NETs) while preventing new NET formation—targeting a key driver of inflammation in rheumatoid arthritis and potentially offering a transformative therapeutic strategy. The company also plans a Phase IIa trial in hidradenitis suppurativa later this year.
